Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev. peru. med. exp. salud publica ; 39(3): 372-375, jul.-sep. 2022. tab
Article in Spanish | LILACS | ID: biblio-1410013

ABSTRACT

RESUMEN Saprochaete capitata es una causa rara de infección fúngica invasiva en pacientes inmunocomprometidos con alta mortalidad y resistencia antifúngica. Presentamos el caso de un niño de cinco años con diagnóstico de aplasia medular, sometido a trasplante de progenitores hematopoyéticos (TPH), que cursó con neutropenia febril persistente, dolor abdominal intenso, aparición de lesiones maculopapulares en piel y deterioro de la función renal. Se identificó la presencia de S. capitata, en hemocultivos transcatéter venoso central. Esta infección fúngica invasiva resulta ser rara, pero emergente y potencialmente mortal, en pacientes con neutropenia febril persistente y uso prolongado de dispositivos invasivos intravasculares como catéter venoso central.


ABSTRACT Saprochaete capitata is a rare cause of invasive fungal infection in immunocompromised patients with high mortality and antifungal resistance. We present the case of a 5-year-old boy with bone marrow aplasia, who underwent hematopoietic stem cell transplantation (HSCT) and presented persistent febrile neutropenia, abdominal pain, appearance of maculopapular lesions on the skin, and impaired renal function. The presence of S. capitata was identified by blood culture from a central venous catheter. This invasive fungal infection is rare but emergent and life-threatening, especially in immunocompromised patients with persistent febrile neutropenia and prolonged use of invasive devices such as central venous catheters.


Subject(s)
Humans , Male , Child, Preschool , Immunocompromised Host , Invasive Fungal Infections/microbiology , Geotrichosis/microbiology , Geotrichum/isolation & purification , Anemia, Aplastic/complications , Fatal Outcome , Invasive Fungal Infections/drug therapy , Geotrichosis/drug therapy , Antifungal Agents/therapeutic use
2.
Rev. peru. med. exp. salud publica ; 36(1): 81-86, ene.-mar. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1004413

ABSTRACT

RESUMEN El objetivo del estudio fue identificar molecularmente cepas de aspergillus aislados de pacientes con aspergilosis invasiva (AI), que fueron tipificadas primariamente como Aspergillus fumigatus sensu lato por métodos fenotípicos convencionales. Se trabajó con 20 cepas de la micoteca de la sección de micología del Instituto de Medicina Tropical "Daniel A. Carrión". Para obtener el ADN fúngico se emplearon las técnicas de choque térmico, tratamiento enzimático y columnas de silica-gel; y se almacenó a -20 0C para conservarlo. En el procedimiento de la reacción en cadena de la polimerasa en tiempo real (qPCR) se incluyeron primers marcados con fluorocromo, los cuales amplificaron las secuencias específicas de A. fumigatus. La fluorescencia se midió con el termociclador al final de la fase de hibridación de cada ciclo. Se identificó molecularmente que sólo el 50% de las cepas estudiadas pertenecen a la especie Aspergillus fumigatus sensu stricto.


ABSTRACT The objective of the study was to identify molecularly-isolated strains of Aspergillus from patients with invasive aspergillosis (IA); these strains were primarily typed as Aspergillus fumigatus sensu lato by conventional phenotypic methods. We worked with 20 strains from the mycology section of the Institute of Tropical Medicine "Daniel A. Carrión." To obtain the fungal DNA, thermal shock, enzymatic treatment, and silica gel column techniques were used; and it was stored at -20°C to preserve it. The real-time polymerase chain reaction (qPCR) procedure included fluorochrome-labeled primers, which amplified the specific sequences of A. fumigatus. Fluorescence was measured with the thermocycler at the end of the hybridization phase of each cycle. It was molecularly-identified that only 50% of the strains studied belong to the species Aspergillus fumigatus sensu stricto.


Subject(s)
Humans , Aspergillosis/microbiology , Aspergillus fumigatus/genetics , Invasive Fungal Infections/microbiology , Aspergillus fumigatus/isolation & purification , DNA, Fungal/analysis
3.
Arch. argent. pediatr ; 116(4): 594-598, ago. 2018. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-950049

ABSTRACT

La infección fúngica invasora ha aumentado en frecuencia a lo largo de la última década, y la sinusitis fúngica es cada vez más habitual. Los hongos del género Exserohilum (familia Pleosporaceae, orden Pleosporales) son filamentosos y dematiáceos, de localización ubicua. Se trata de patógenos emergentes, que producen, en la mayoría de los casos, infecciones sistémicas que afectan, principalmente, a los senos paranasales y los pulmones. Son más frecuentes en pacientes inmunosuprimidos, aunque pueden presentarse en pacientes inmunocompetentes. El tratamiento de estas infecciones comprende el tratamiento antifúngico, resección quirúrgica y restitución de la inmunidad. Se presenta el caso de una paciente con recaída medular de leucemia linfoblástica aguda con sinusitis fúngica invasiva por Exserohilum rostratum.


Invasive fungal infection has increased in frequency over the last decade, with fungal sinusitis becoming more frequent. The fungi of the genus Exserohilum (family Pleosporaceae, order Pleosporales) are filamentous and dematiaceous of ubiquitous location. It is an emerging pathogen, which in most cases produces a systemic infection that mainly affects the paranasal sinuses and lungs. It is more common in immunosuppressed patients, although it may occur in immunocompetent patients. The treatment is based on three pillars: antifungal treatment, surgical debridement and restitution of immunity. We present the case of a patient with medullary relapse of acute lymphoblastic leukemia with invasive fungal sinusitis by Exserohilum rostratum.


Subject(s)
Humans , Female , Child, Preschool , Ascomycota/isolation & purification , Sinusitis/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Invasive Fungal Infections/diagnosis , Recurrence , Sinusitis/microbiology , Sinusitis/therapy , Acute Disease , Debridement/methods , Invasive Fungal Infections/microbiology , Invasive Fungal Infections/therapy , Antifungal Agents/therapeutic use
4.
Arch. argent. pediatr ; 116(3): 451-454, jun. 2018. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-950025

ABSTRACT

La información sobre el uso de posaconazol en niños es escasa. Se realizó este estudio descriptivo retrospectivo entre agosto de 2010 y marzo de 2017 para evaluar las características clínicas, microbiológicas y la evolución de los pacientes tratados con posaconazol. Se incluyeron 16 niños. Mediana de edad: 161 meses (rango intercuartílico -RIC- 69-173 m). Todos tenían enfermedad subyacente y presentaban infección fúngica invasiva probada. Los aislamientos más frecuentes fueron Mucor spp. y Aspergillus spp. La dosis media de posaconazol fue 600 mg/día (400-800 mg/día) y la mediana de duración del tratamiento, 223 días (RIC 48-632). Diez pacientes presentaron efectos adversos, pero solo uno requirió suspensión del antifúngico debido a alteraciones hidroelectrolíticas.


There is limited information on the use of posaconazole in children. This retrospective and descriptive study was conducted to evaluate the clinical, microbiological characteristics and evolution of patients treated with posaconazole between August 2010 and March 2017. We included 16 children. Median age: 161 months (interquartile range -IQR-69-173m). All had underlying disease and a proven invasive fungal infection. The most frequent isolated were Mucor spp. and Aspergillus spp. The mean posaconazole dose was 600 mg /day (400-800 mg/day) and the median duration of treatment was 223 days (IQR 48-632). Ten patients had adverse effects, but only one required suspension of the antifungal treatment due to hydroelectrolytic disorders.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Triazoles/therapeutic use , Invasive Fungal Infections/drug therapy , Antifungal Agents/therapeutic use , Time Factors , Triazoles/administration & dosage , Triazoles/adverse effects , Retrospective Studies , Dose-Response Relationship, Drug , Tertiary Care Centers , Invasive Fungal Infections/microbiology , Hospitals, Pediatric , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects
5.
Rev. Soc. Bras. Med. Trop ; 50(1): 80-85, Jan.-Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-842812

ABSTRACT

ABSTRACT INTRODUCTION: Invasive fungal infections (IFIs) are an important complication in immunocompromised individuals, particularly neutropenic patients with hematological malignancies. In this study, we aimed to verify the epidemiology and diagnosis of IFIs in patients with hematologic problems at a tertiary hospital in Goiânia-GO, Brazil. METHODS: Data from 117 patients, involving 19 cases of IFIs, were collected. The collected data included diagnosis methods, demographics, clinical characteristics, and in vitro susceptibility to different antifungal agents. Among the 19 cases, 12 were classified as proven IFI and 7 as probable invasive aspergillosis with detection of galactomannan in blood and presence of lung infiltrates in radiographic images. Logistic regression analysis showed that the proven and probable IFIs were associated with increased risk of death. Statistical analysis demonstrated that age, sex, and underlying disease were not independently associated with risk of death in IFI patients. RESULTS: Most bloodstream isolates of Candida spp. exhibited low minimum inhibitory concentrations (MICs) to all antifungal agents tested. Voriconazole and amphotericin had the lowest MICs for Aspergillus spp. and Fusarium spp., but Fusarium spp. showed the least susceptibility to all antifungals tested. Amphotericin B, fluconazole, and itraconazole were found to be inactive in vitro against Acremonium kiliense; but this fungus was sensitive to voriconazole. CONCLUSIONS: Considering the high number of IFI cases, with crude mortality rate of 6%, we could conclude that IFIs remain a common infection in patients with hematological malignancies and underdiagnosed ante mortem. Thus, IFIs should be monitored closely.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Invasive Fungal Infections/microbiology , Hematologic Diseases/microbiology , Aspergillus/isolation & purification , Aspergillus/drug effects , Acremonium/isolation & purification , Acremonium/drug effects , Candida/isolation & purification , Candida/drug effects , Microbial Sensitivity Tests , Prevalence , Sensitivity and Specificity , Immunocompromised Host , Invasive Fungal Infections/diagnosis , Fusarium/isolation & purification , Fusarium/drug effects , Mannans/blood , Middle Aged , Antifungal Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL